<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999349</url>
  </required_header>
  <id_info>
    <org_study_id>187050</org_study_id>
    <secondary_id>LE13K0.52,</secondary_id>
    <secondary_id>IRCT138804022067N1</secondary_id>
    <nct_id>NCT00999349</nct_id>
  </id_info>
  <brief_title>Therapeutic Effects of Silymarin in Patients With B-thalassemia Major</brief_title>
  <official_title>Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Madaus Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      Silymarin, a flavonolignan complex isolated from Silybum marianum, has a strong antioxidant,
      hepatoprotective and iron chelating activities. The present study has been designed to
      investigate the therapeutic activity of orally administered silymarin in patients with
      thalassemia major under conventional iron chelation therapy. A 6-month randomized,
      double-blind, clinical trial was conducted in 140 beta-thalassemia major patients in two
      well-matched groups. Patients are randomized to receive a silymarin tablet (140 mg) three
      times a day plus conventional desferrioxamine therapy or the same therapy but a placebo
      tablet instead of silymarin. Clinical laboratory tests of iron status and liver function are
      assessed at the beginning and the end of the trial.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <primary_completion_date type="Anticipated">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum ferritin level</measure>
    <time_frame>after 3 months and 6 months from beginning of the trial</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver enzymes (SGOT, SGPT, Alkaline Phosphatase), serum Hepcidin, and soluble transferrin receptor levels</measure>
    <time_frame>At the beginning and the end of the trial</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Beta-thalassemia Major</condition>
  <condition>Iron Overload</condition>
  <arm_group>
    <arm_group_label>Silymarin (LEGALON)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silymarin (LEGALON)</intervention_name>
    <description>Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg</description>
    <arm_group_label>Silymarin (LEGALON)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of major Beta-thalassemia

          -  Age 12 years or older

          -  Iron overload condition (serum ferritin levels between 1000-5000 ng/mL) Regular
             desferrioxamine administration (50 mg/kg)

          -  Continuous blood transfusions

          -  Negative CRP test

        Exclusion criteria:

          -  Hepatitis B or C infection

          -  Positive HIV test

          -  Chronic renal or heart failure

          -  Iron chelating therapy with other iron chelators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Behjat Moayedi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan University of Medical Sciences, moayedi@med.mui.ac.ir</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Isfahan University of Medical Sciences</name>
      <address>
        <city>Isfahan</city>
        <zip>81744-176</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://www.irct.ir/</url>
    <description>Iranian Registry of Clinical Trials</description>
  </link>
  <reference>
    <citation>Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial. Fundam Clin Pharmacol. 2009 Jun;23(3):359-65. doi: 10.1111/j.1472-8206.2009.00681.x. Epub 2009 May 7.</citation>
    <PMID>19453758</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <last_update_submitted>October 20, 2009</last_update_submitted>
  <last_update_submitted_qc>October 20, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Professor Behjat Moayedi</name_title>
    <organization>Isfahan University of Medical Sciences</organization>
  </responsible_party>
  <keyword>iron overload condition</keyword>
  <keyword>regular desferrioxamine administration</keyword>
  <keyword>receiving continuous blood transfusions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silymarin</mesh_term>
    <mesh_term>Deferoxamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

